VN 0200
Alternative Names: VN-0200Latest Information Update: 13 Mar 2024
At a glance
- Originator Daiichi Sankyo Company
- Class Antivirals; Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Respiratory syncytial virus infections
Most Recent Events
- 15 Feb 2024 Daiichi Sankyo Company completes a phase-II trial in Respiratory syncytial virus infections in Japan (NCT05547087)
- 13 Oct 2022 Phase-II clinical trials in Respiratory syncytial virus infections (Prevention, In adults, In the elderly) in Japan (IM) (NCT05547087)
- 21 Sep 2022 Daiichi Sankyo plans a phase II trial for Respiratory syncytial virus infections (Prevention) in Japan (IM, Injection) in December 2022 (NCT05547087)